Inflammatory bowel disease (IBD) is a spectrum of diseases characterized by the interplay of the aberrant immune system, genetic factors, environmental factors, and intestinal microbiota, resulting in relapsing inflammation of the gastrointestinal tract. Underlying pro-inflammatory state and immune dysregulation act as a catalyst for increasing the likelihood of developing extraintestinal manifestations, including cardiovascular diseases (CVD) like atherosclerosis, pericarditis, myocarditis, venous and arterial thromboembolism, arrhythmias, despite a lower prevalence of classic CVD risk factors, like high body mass index or dyslipidemia compared to the general population. Chronic inflammation damages endothelium resulting in the recruitment of inflammatory cells, which induce cytotoxicity, lipoprotein oxidation, and matrix degradation, which increases the risk of atherosclerosis. Additionally, intestinal dysbiosis disrupts the intestinal mucosal barrier, releasing endotoxins and lipopolysaccharides into circulation, further exaggerating the atherosclerotic process. Abnormal collagen metabolism and alteration of nitric oxide-mediated vasodilation lead to blood pressure dysregulation in patients with IBD. Therefore, it is essential to make lifestyle modifications like smoking cessation, dietary changes, and increasing physical activity with adherence to medication to mitigate the risk of developing CVD in patients with IBD. This article reviews the potential links between IBD and the increased risk of CVD in such individuals.
Citations
Citations to this article as recorded by
Association Between Inflammatory Bowel Disease and Venous Leg Ulcers: Insight From Mendelian Randomization Analyses Yanfeng Lin, Xiaohui Qin, Haiyan Zhang, Jinke Huang, Xingshun Qi Canadian Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Metabolic Disorders and Inflammatory Bowel Diseases Hye Kyung Hyun, Jae Hee Cheon Gut and Liver.2025; 19(3): 307. CrossRef
Carnitine: Its Crucial Role in Metabolic Health and Cardiovascular Function Fremita Fredrick, Kanishk Aggarwal, Anish Kumar Reddy Meda, Fnu Anamika, Amishi Singla, Pranjal Jain, Rohit Jain Journal of Dietary Supplements.2025; 22(5): 664. CrossRef
The gut-heart axis: a correlation between Paneth cells’ dysfunction, microbiome dysbiosis, and cardiovascular diseases Aysa Rezabakhsh, Solomon Habtemariam, Rezayat Parvizi, Anne Meddahi-Pellé, Violeta Rodriguez Ruiz, Graciela Pavon-Djavid, Abolfazl Barzgari Cell Communication and Signaling.2025;[Epub] CrossRef
Study design of ‘PASIBO’ - co-creation and development of a physical activity intervention to patients with inflammatory bowel disease Tanja Thomsen, Marie Villumsen, Anja Poulsen, Anders B. G. Hansen, Bente A. Esbensen, Tine Jess, Mette Aadahl BMC Health Services Research.2025;[Epub] CrossRef
From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD’s Cardiometabolic Risks Oscar Noble, Dayoung Jeon, Megan Lewis, Christopher Fan, Khurram Nasir, Bincy P. Abraham Current Atherosclerosis Reports.2025;[Epub] CrossRef
Cardiovascular Complications Are Increased in Inflammatory Bowel Disease: A Path Toward Achievement of a Personalized Risk Estimation Vito Annese, Maria Laura Annunziata, Guglielmo Albertini Petroni, Emanuele Orlando, Sofia Cinque, Marzio Parisi, Paolo Biamonte, Giuseppe Dell’Anna, Anna Latiano, Serenella Castelvecchio Journal of Personalized Medicine.2025; 15(9): 418. CrossRef
Coagulopathy and platelet abnormalities in patients with inflammatory bowel disease Dae Sung Kim, Won Moon The Korean Journal of Internal Medicine.2025; 40(6): 866. CrossRef
Clinical Outcomes of Venous Thromboembolism in Patients with Ankylosing Spondylitis vs. Other Immune-mediated Inflammatory Diseases: Insights from the RIETE Registry Romain Chopard, Gregory Piazza, Laurent Bertoletti, Nicolas Meneveau, Leticia Guirado, José Antonio Porras, Francisco Rivera-Cívico, José Felipe Varona Arche, Manuel Monreal, Clément Prati Thrombosis and Haemostasis.2025;[Epub] CrossRef